MRK ▲ +0.4% - Merck & Co., Inc.
$MRK - Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
25-SEP-2026 04:40 PM ET
Share this post
More filings for $MRK
MRK ▼ -0.5% - Merck & Co., Inc.Nov 3, 2026MRK ▲ +2.8% - Merck & Co., Inc.Oct 29, 2026MRK ▼ -2.4% - Merck & Co., Inc.Oct 26, 2026MRK ▼ -1.9% - Merck & Co., Inc.Oct 23, 2026MRK ▼ -0.9% - Merck & Co., Inc.Oct 22, 2026MRK ▼ -0.9% - Merck & Co., Inc.Oct 22, 2026
View full $MRK filing history →💬 Comments
Loading comments…
Leave a comment